TAK:NYSE (Japan) Also trade in: Germany Japan Mexico Switzerland UK

Takeda Pharmaceutical Co Ltd

$ 18.27 0.12 (0.63%)
On watch
Volume: 1,714,474 Avg Vol (1m): 2,237,808
Market Cap $: 56.69 Bil Enterprise Value $: 62.84 Bil
P/E (TTM): 29.24 P/B: 1.57
Earnings Power Value 7.46
Net Current Asset Value -6.06
Tangible Book -0.2
Projected FCF 14.69
Median P/S Value 22.24
Graham Number 0
Peter Lynch Value 4.66
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.73
Equity-to-Asset 0.35
Debt-to-Equity 1.25
Debt-to-EBITDA 7.31
Interest Coverage 3.68
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.20
DISTRESS
GREY
SAFE
Beneish M-Score -2.88
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 5.92%
WACC 3.36%

Profitability & Growth : 6/10

Current vs industry vs history
Operating Margin % 11.45
Net Margin % 6.20
ROE % 5.33
ROA % 2.43
ROC (Joel Greenblatt) % 32.55
3-Year Total Revenue Growth Rate -0.10
3-Year Total EBITDA Growth Rate 42.70

» TAK's 30-Y Financials

Financials (Next Earnings Date: 2019-07-31)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:TAK

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS : 325412    SIC : 2834
Compare SHSE:600276 NYSE:ZTS XTER:MRK NAS:MYL TSE:4523 NSE:SUNPHARMA SHSE:600518 NYSE:TEVA TSE:4507 SZSE:000538 SHSE:600196 XPAR:IPN NYSE:AGN OCSE:LUN NYSE:PRGO TSE:4508 SZSE:000963 XSWX:VIFN SZSE:300122 JSE:APN
Traded in other countries TKD.Germany 4502.Japan 4502.Switzerland 0RN3.UK
Address 4-1-1 Doshomachi, Chuo-ku, Osaka, JPN, 540-8645
Takeda is Japan's largest pharmaceutical company, with annual revenue around $16 billion and a focus on four therapeutic areas: oncology, gastroenterology, vaccines, and neurology. Roughly 40% of its revenue comes from Japan. The Millennium acquisition (2008) brought rights to Velcade, Ninlaro, and Entyvio. The Nycomed acquisition (2011) expanded Takeda's exposure to Europe and emerging markets. Other notable products include Azilva (blood pressure), leuprorelin (prostate cancer), and Trintellix (depression).

Ratios

Current vs industry vs history
PE Ratio (TTM) 29.24
Forward PE Ratio 12.94
N/A
PE Ratio without NRI 29.24
Price-to-Owner-Earnings 15.38
PB Ratio 1.57
PS Ratio 1.81
Price-to-Free-Cash-Flow 14.51
Price-to-Operating-Cash-Flow 9.56
EV-to-EBIT 36.39
EV-to-EBITDA 20.14
EV-to-Revenue 3.94
PEG Ratio 13.86
Shiller PE Ratio 20.88
Current Ratio 3.06
Quick Ratio 2.81
Days Inventory 169.49
Days Sales Outstanding 104.42
Days Payable 188.76

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 4.39
Dividend Payout Ratio 1.26
Forward Dividend Yield % 4.36
N/A
Yield-on-Cost (5-Year) % 4.42
3-Year Share Buyback Rate -0.10

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.24
Price-to-Median-PS-Value 0.82
Price-to-Peter-Lynch-Fair-Value 3.92
Earnings Yield (Joel Greenblatt) % 2.74
Forward Rate of Return (Yacktman) % 11.30

More Statistics

Revenue (TTM) (Mil) $ 16,161.93
EPS (TTM) $ 0.61
Beta 1.03
Volatility % 29.57
52-Week Range $ 15.5 - 23.95
Shares Outstanding (Mil) 3,103.25

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA Y
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy N
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy N